Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
U. Gatzemeier(Heidelberg University), Maurizio Voi(Metis Design Corporation (United States)), Maya Gottfried(Meir Medical Center), R. Rosso, Frances A. Shepherd(Princess Margaret Hospital), Ronald L. Burkes(Mount Sinai Hospital), H.J.M. Groen(Martini Ziekenhuis), B. Cottier(Clatterbridge Cancer Centre NHS Foundation Trust), K. Mattson(Asklepios Fachkliniken München-Gauting), Thierry Le Chevalier(Institut Gustave Roussy), P. Weynants, H. Cortés-Funes(Centre Hospitalier René-Dubos), Maurizio Tonato
Cited by 242
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k